On September 21, INNOCARE rose 5.1% in regular trading, trading at HK$15.66/share, with turnover of HK$19.16 million. The stock gained momentum amid a broader rally in the innovative drug sector.

On the news front, INNOCARE recently received approval from China's National Medical Products Administration to initiate clinical trials for ICP-B381, a bispecific antibody-drug conjugate (ADC) targeting both PSMA and STEAP1 for the treatment of prostate cancer and other solid tumors. ICP-B381 is the world's first bispecific ADC targeting this dual combination and the company's first bispecific ADC developed on its proprietary platform, featuring a next-generation irreversible linker and potent payload. Preclinical data showed superior efficacy over corresponding single-target PSMA ADC and STEAP1 ADC at equivalent doses, with favorable tolerability.

Fundamentally, the company reported H1 revenue of RMB 1.137 billion, up 55.46% year-over-year, and attributable net profit of RMB 246 million, surging 918.69% year-over-year, marking a sustained return to profitability. Drug sales revenue reached RMB 918 million, driven by continued ramp-up of BTK inhibitor orelabrutinib and contributions from newly launched products.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)